# Genextra

> Genextra is a VC fund in Milan backing Health Care and Biotechnology. See 7 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Milan, Italy
- Total investments: 7
- Last investment: Jan 2022
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/755921
- Website: http://www.genextra.it/

Genextra is a VC fund in Milan focused on Health Care and Biotechnology. Their mission is to identify innovative research in life science and to develop novel therapies and tools by creating successful business initiatives in a sustained and long term way.Genextra's holding structure is designed to increase the probability of success of business initiatives that become part of the Group by providing specialistmanagement as well as financial support to a new company vehicle or an existing young start-up.Genextra was created in 2004 by a group of prominent Italian entrepreneurs and financial institutions in partnership with leading scientists from the European Institute of Oncology (IEO).To date, Genextra has raised over €116 million and represents one of very few examples in Italy of private capital invested for the benefit of research and innovation.

## Contacts

5 contacts available for Genextra. Shizune tracks 1 team members at Genextra. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/genextra?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Biotechnology | 2 | 29% |
| Pharmaceutical | 2 | 29% |
| Medical | 1 | 14% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Series A | 1 | 14% |
| Series C | 1 | 14% |
| Funding Round | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Italy | 2 | 29% |
| United States | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Paolo Fundaro | CFO | 6 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| InnovHeart | InnovHeart s.r.l develops Transcatheter Mitral Valve Replacement systems (TMVR) to treat patients suffering from mitral valve disease. The company is conducting clinical trials of its novel Saturn TMVR system. | $55M | Series C | Jan 27, 2022 |  |
| InnovHeart | InnovHeart s.r.l develops Transcatheter Mitral Valve Replacement systems (TMVR) to treat patients suffering from mitral valve disease. The company is conducting clinical trials of its novel Saturn TMVR system. | $23.6M | Series B | Aug 07, 2020 |  |
| Erydel | Based in Urbino, EryDel has developed and patented a technology for drug delivery of pharmacological agents through erythrocytes (red blood cells). This process allow to easily load red blood cells with drugs, proteins, contrasting agents for diagnostic purposes, nanoparticles etc. that can be progressively released into the patient body thusallowing an increased efficacy of the therapy and a reduction of collateral effects. The benefit is extremely significant particularly for chronic pathologies that requires continuous daily treatments for patients which could be substituted by monthly transfusion of blood loaded with specific therapeutic agents. Currently, the solution has been tested by several patients for the treatment of Inflammatory Bowel Diseases (IBDs) such as ulcer colitis and Crohn disease. The company can provide a complete support for the drug delivery process including a specific device for the erythrocytes loading ("Red Cell Loader"), and disposable kits. | $29.1M | Series B | Apr 24, 2018 |  |
| Erydel | Based in Urbino, EryDel has developed and patented a technology for drug delivery of pharmacological agents through erythrocytes (red blood cells). This process allow to easily load red blood cells with drugs, proteins, contrasting agents for diagnostic purposes, nanoparticles etc. that can be progressively released into the patient body thusallowing an increased efficacy of the therapy and a reduction of collateral effects. The benefit is extremely significant particularly for chronic pathologies that requires continuous daily treatments for patients which could be substituted by monthly transfusion of blood loaded with specific therapeutic agents. Currently, the solution has been tested by several patients for the treatment of Inflammatory Bowel Diseases (IBDs) such as ulcer colitis and Crohn disease. The company can provide a complete support for the drug delivery process including a specific device for the erythrocytes loading ("Red Cell Loader"), and disposable kits. | $16.5M | Series B | Jul 01, 2013 |  |
| Intercept Pharmaceuticals | Intercept Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, a FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programsalso focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases. Intercept Pharmaceuticals, Inc. was founded in 2002 and is based in New York, New York. | $41M |  | May 16, 2006 |  |
| Intercept Pharmaceuticals | Intercept Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, a FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programsalso focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases. Intercept Pharmaceuticals, Inc. was founded in 2002 and is based in New York, New York. | $25M | Series B |  |  |
| Intercept Pharmaceuticals | Intercept Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, a FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programsalso focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases. Intercept Pharmaceuticals, Inc. was founded in 2002 and is based in New York, New York. | $25M | Series A |  |  |

7 of 7 investments shown.

## Co-investors
- [Indaco Venture Partners](https://shizune.co/investors/profile/indaco-venture-partners) — VC Fund, 2 deals together
- [Innogest Capital](https://shizune.co/investors/profile/innogest-sgr) — VC Fund, 2 deals together
- [Panakes Partners](https://shizune.co/investors/profile/panakes-partners) — VC Fund, 2 deals together
- [Balyasny Asset Management](https://shizune.co/investors/profile/balyasny-asset-management) — VC Fund, 1 deal together
- [CDP Venture Capital](https://shizune.co/investors/profile/cdp-venture-capital) — VC Fund, 1 deal together
- China Grand Pharmaceutical and Healthcare Holdings — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Genextra invest in?

Genextra invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Genextra?

Public channels for Genextra include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Genextra?

The team at Genextra includes Paolo Fundaro (CFO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co